The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site
Open accessAbstract
SUMMARY Epstein-Barr virus (EBV) represents a major global health problem. Though it is associated with infectious mononucleosis and over 200,000 cancers annually worldwide, a vaccine is not available. The major target of immunity is EBV glycoprotein 350/220 (gp350) that mediates attachment to B cells through complement receptor 2 (CR2/CD21). Here, we created self-assembling nanoparticles that displayed different domains of gp350 in a symmetric array. By focusing presentation of the CR2-binding domain on nanoparticles, potent neutralizing antibodies were elicited in mice and non-human primates. The structurally designed nanoparticle vaccine improved vaccine-induced protection in a mouse model by targeting a functionally conserved site of vulnerability with 10- to 100-fold increased neutralization compared to soluble gp350. This rational approach to EBV vaccine design elicited potent neutralizing antibody responses by focusing on a conserved viral entry domain, a strategy that can be applied to other viruses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA
Epstein, M. A., Achong, B. G., & Barr, Y. M. (1964) · The Lancet · doi:10.1016/s0140-6736(64)91524-7 · Cited by 2,778
Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1
Wu, X., Yang, Z.-Y., Li, Y., Hogerkorp, C.-M., Schief, W. R., Seaman, M. S., Zhou, T., Schmidt, S. D., Wu, L., Xu, L., et al. (2010) · Science · doi:10.1126/science.1187659 · Cited by 1,730
Self-citationStructural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Zhou, T., Georgiev, I., Wu, X., Yang, Z.-Y., Dai, K., Finzi, A., Do Kwon, Y., Scheid, J. F., Shi, W., Xu, L., et al. (2010) · Science · doi:10.1126/science.1192819 · Cited by 1,130
Self-citationEpstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.
Fingeroth, J. D., Weis, J. J., Tedder, T. F., Strominger, J. L., Biro, P. A., & Fearon, D. T. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.14.4510 · Cited by 939
Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies
Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., & Nabel, G. J. (2013) · Nature · doi:10.1038/nature12202 · Cited by 885
Self-citationRational HIV Immunogen Design to Target Specific Germline B Cell Receptors
Jardine, J., Julien, J.-P., Menis, S., Ota, T., Kalyuzhniy, O., McGuire, A., Sok, D., Huang, P.-S., MacPherson, S., Jones, M., et al. (2013) · Science · doi:10.1126/science.1234150 · Cited by 770
Engineering synthetic vaccines using cues from natural immunity
Irvine, D. J., Swartz, M. A., & Szeto, G. L. (2013) · Nature Materials · doi:10.1038/nmat3775 · Cited by 594
Magnetoferritin: in Vitro Synthesis of a Novel Magnetic Protein
Meldrum, F. C., Heywood, B. R., & Mann, S. (1992) · Science · doi:10.1126/science.1636086 · Cited by 572
Okuno, Y., Isegawa, Y., Sasao, F., & Ueda, S. (1993) · Journal of Virology · doi:10.1128/jvi.67.5.2552-2558.1993 · Cited by 489
Cross-neutralization of influenza A viruses mediated by a single antibody loop
Ekiert, D. C., Kashyap, A. K., Steel, J., Rubrum, A., Bhabha, G., Khayat, R., Lee, J. H., Dillon, M. A., O’Neil, R. E., Faynboym, A. M., et al. (2012) · Nature · doi:10.1038/nature11414 · Cited by 481
Cited by
COVID-19 vaccine development and a potential nanomaterial path forward
Shin, M. D., Shukla, S., Chung, Y. H., Beiss, V., Chan, S. K., Ortega-Rivera, O. A., Wirth, D. M., Chen, A., Sack, M., Pokorski, J. K., et al. (2020) · Nature Nanotechnology · doi:10.1038/s41565-020-0737-y · Cited by 659
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
Huang, Y., Guo, X., Wu, Y., Chen, X., Feng, L., Xie, N., & Shen, G. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01745-z · Cited by 490
Latency and lytic replication in Epstein–Barr virus-associated oncogenesis
Münz, C. (2019) · Nature Reviews Microbiology · doi:10.1038/s41579-019-0249-7 · Cited by 469
Marcandalli, J., Fiala, B., Ols, S., Perotti, M., de van der Schueren, W., Snijder, J., Hodge, E., Benhaim, M., Ravichandran, R., Carter, L., et al. (2019) · Cell · doi:10.1016/j.cell.2019.01.046 · Cited by 448
Metadata
- Authors
- Kanekiyo, M., Bu, W., Joyce, M. G., Meng, G., Whittle, J. R. R., Baxa, U., Yamamoto, T., Narpala, S., Todd, J.-P., Rao, S. S., McDermott, A. B., Koup, R. A., Rossmann, M. G., Mascola, J. R., Graham, B. S., Cohen, J. I., & Nabel, G. J.
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 1090-1100
- ISSN
- 0092-8674 (ISSN-L)
- OpenAlex
- W2162802735
- Cited by
- 366
- References
- 50
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. https://app.cochat.ai/papers/10.1016/j.cell.2015.07.043
- The paper
- Kanekiyo, M., Bu, W., Joyce, M. G., Meng, G., Whittle, J. R. R., Baxa, U., Yamamoto, T., Narpala, S., Todd, J.-P., Rao, S. S., McDermott, A. B., Koup, R. A., Rossmann, M. G., Mascola, J. R., Graham, B. S., Cohen, J. I., & Nabel, G. J. (2015). Rational Design of an Epstein-Barr Virus Vaccine Targeting the Receptor-Binding Site. Cell. https://doi.org/10.1016/j.cell.2015.07.043
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
